Asset Type: Brochures, Discovery, Preclinical Imaging, CNS, Radiopharmaceutical 
Therapy & Theranostics

In Vivo Preclinical Research Services for Oncology, CNS, and Advanced Therapeutics

In Vivo Preclinical Research Services for Oncology, CNS, and Advanced Therapeutics

Generate decision-ready data with integrated preclinical imaging and translational research expertise.

In vivo studies play a critical role in understanding how therapeutic candidates distribute, engage biological targets, and perform in complex disease models. Generating reliable, quantitative data requires the right combination of scientific expertise, validated models, and advanced imaging technologies.

Perceptive Discovery provides integrated in vivo research services across oncology, neuroscience, and advanced therapeutics. Our teams combine preclinical models, radiochemistry, molecular imaging, and quantitative analysis to support candidate evaluation and IND-enabling development.

What You’ll Learn

Download our In Vivo Services flyer to explore:

  • Oncology research models: CDX, PDX, syngeneic, and orthotopic models supporting biodistribution, efficacy, and combination therapy studies.
  • CNS research capabilities: Target occupancy, neuropharmacodynamic imaging, neuroinflammation, and neurodegeneration models.
  • Advanced imaging modalities: PET, SPECT, Alpha-SPECT™, MRI, CT, and optical imaging technologies.
  • Integrated study capabilities: Biodistribution, PK/PD assessment, target engagement, efficacy, and dosimetry.
  • Translational research support: Rodent, large animal, and nonhuman primate studies to inform clinical development decisions.

Discover how our integrated approach connects in vivo biology, imaging, and quantitative analysis to generate meaningful insights throughout preclinical development.

Logo

Supporting Preclinical Radioligand Therapy Research

In vivo studies are essential for evaluating radioligand therapy biodistribution, tumor targeting, therapeutic efficacy, and potential toxicity. Perceptive Discovery combines disease models, molecular imaging, radiochemistry, and dosimetry to support the evaluation of alpha- and beta-emitting radiopharmaceuticals.